US Stock MarketDetailed Quotes

TCRX TScan Therapeutics

Watchlist

4.770
0.0000.00%

Close Nov 29 13:00 ET

4.770
0.0000.00%

Post 17:01 ET

254.58MMarket Cap-5021P/E (TTM)

TScan Therapeutics Stock Forum

Jaguar8

Nov 5 08:16

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Jaguar8

Oct 4 10:40

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...

Trytosaveabit

May 29 06:08

News

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
Benzinga· 2 mins ago

Trytosaveabit

May 9 06:08

Watching

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Inc - on-Track to Report Initial Data From Solid Tumor Clinical Trial in 2024

Jaguar8

May 9 06:04

$TScan Therapeutics (TCRX.US)$
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Jaguar8

Apr 19 09:36

$TScan Therapeutics (TCRX.US)$
NEWS
TScan Therapeutics Announces Closing of Upsized Public Offering

Trytosaveabit

Apr 16 15:25

Grrr

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Trytosaveabit

Apr 16 15:02

Update

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Inc -Patients Identified Across All Six Tcr-T Cohorts in Solid Tumor Program With Dosing of First Three Expected in Early May

Trytosaveabit

Mar 6 06:14

Pretty nice!

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 73.08 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $7.21 million which beat the analyst consensus estimate of $3.34 million by 115.90 percent. This is a 132.91 percent increase over sales of $3.10 million the same period...

Trytosaveabit

Oct 25, 2023 08:12

Hmmm!

$TScan Therapeutics (TCRX.US)$

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data